|
Hyperalgesia
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The protein levels of PD-L1 were significantly increased 2 h, 4 h and 6 h after treatment, and PD-1 was significantly increased at 2 h and 6 h. The blockade of PD-1 increased acute nitroglycerin-induced hyperalgesia, and this effect was accompanied by a more significant increase in calcitonin gene-related peptide, IL-1β, TNF-α, IL-6 and IL-18 in the trigeminal ganglia.
|
31640402 |
2020 |
|
Myopathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Here, we report the clinical and pathological findings of nine unrelated patients with PD-1 and PD-L1 inhibitors-associated myopathy.
|
31838162 |
2020 |
|
Paresis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We identified 9 patients receiving anti-PD-1 or PD-L1 inhibitors consulting for either muscle weakness, asthenia, myasthenic-like syndrome or other muscle related-symptoms, along with biopsy-proven inflammatory myopathy.One had concomitant myocarditis.
|
31838162 |
2020 |
|
Situs Inversus
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PD1/PD-L1 pathway contributes to the pathogenesis of HIV/SIV infection and blockade of this pathway may have potential to restore immune function and promote viral control/elimination.
|
31562760 |
2020 |
|
Thyrotoxicosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Of 91 patients treated with a PD-L1 inhibitor, 19 (21%) developed new onset thyroid dysfunction, of which 14 presented with hypothyroidism and 5 with thyrotoxicosis (3 progressed to hypothyroidism, 2 returned to euthyroidism), and 4 (4%) had worsening of preexisting hypothyroidism.
|
31813343 |
2020 |
|
Migraine Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the role of PD-L1/PD-1 in migraine remains unclear.
|
31640402 |
2020 |
|
Muscle Weakness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We identified 9 patients receiving anti-PD-1 or PD-L1 inhibitors consulting for either muscle weakness, asthenia, myasthenic-like syndrome or other muscle related-symptoms, along with biopsy-proven inflammatory myopathy.One had concomitant myocarditis.
|
31838162 |
2020 |
|
Follicular adenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Negative PD-L1 expression was found in NIFTPs and FAs.
|
31821747 |
2020 |
|
Olfactory Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Of the four available metastatic samples arising from PD-L1 negative primary site ONB, three were positive for PD-L1 of which all were found to contain PD-1<sup>+</sup> tumor cells.
|
31785431 |
2020 |
|
Pituitary-dependent Cushing's disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study confirms PD-L1 expression on functioning pituitary adenomas and is the first to evaluate the efficacy of checkpoint blockade (anti-PD-L1) therapy in a preclinical model of Cushing's Disease (CD).
|
31744830 |
2020 |
|
Circling gait
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Personalized detection of circling exosomal PD-L1 based on Fe<sub>3</sub>O<sub>4</sub>@TiO<sub>2</sub> isolation and SERS immunoassay.
|
31678824 |
2020 |
|
Granulomatous hepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pembrolizumab and atezolizumab manifested not only lobular hepatitis but also sclerosing cholangitis, lymphocytic duct injury and granulomatous hepatitis, probably representing various impaired cellular functions in CD8<sup>+</sup> lymphocytes and macrophages due to blockage of PD-1-PD-L1 interaction.
|
31550390 |
2020 |
|
Lymphocytic hypopituitarism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The frequent emergence of lymphocytic hypophysitis following checkpoint blockade for other cancers, as well as the expression of PD-L1 on pituitary adenomas, suggest a role for immunotherapy.
|
31744830 |
2020 |
|
Sarcomatoid Mesothelioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD274 expression was associated with sarcomatoid mesothelioma and high infiltration of CD8<sup>+</sup> lymphocytes.
|
31363159 |
2020 |
|
Autoimmune Hypophysitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The frequent emergence of lymphocytic hypophysitis following checkpoint blockade for other cancers, as well as the expression of PD-L1 on pituitary adenomas, suggest a role for immunotherapy.
|
31744830 |
2020 |
|
MOHR-TRANEBJAERG SYNDROME
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The effects of miR-34a-5p mimic on DDP-treated SKOV3/DDP cells were reversed by the overexpression of PD-L1.
|
31777260 |
2020 |
|
Nongerminomatous Germ Cell Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Robust PD-L1+ TAMs are significantly expanded in seminomas compared with NSGCTs.
|
31802108 |
2020 |
|
Cutaneous lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas.
|
31163235 |
2020 |
|
Acute migraine
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study we evaluated the expression and role of PD-L1/PD-1 in the trigeminal ganglia in an animal model of acute migraine.
|
31640402 |
2020 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our finding uncovers the antitumorigenic effect of CHL in T-ALL progression through upregulating the expression of miR-9 and suppressing PD-L1 expression, which may provide a new potential strategy for T-ALL clinical treatment.
|
31836919 |
2020 |
|
Stage IV Uterine Corpus Cancer AJCC v6
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we describe the case of a patient with MMR-proficient, PD-L1-negative stage IV endometrial cancer who exhibited a strong clinical response to combination PD-1 and CTLA-4 inhibition.
|
30247204 |
2020 |
|
Platinum-Resistant Urothelial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint inhibitors (ICIs) are approved for first-line (cisplatin unfit, PD-L1+) and platinum-refractory urothelial carcinoma (UC).
|
31699525 |
2020 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluated PD-L1 expression in a large series of TCs (20 cases) showing a progressive dedifferentiation of the thyroid tumor from well differentiated TC to ATC, employing two different antibodies [R&D Systems and VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody].
|
30762153 |
2019 |
|
Ataxia Telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
ATC = anaplastic thyroid cancer; DTC = differentiated thyroid cancer; IHC = immunohistochemical; OS = overall survival; PD-1 = programmed cell death-receptor 1; PD-L1 = programmed cell death-ligand 1; PD-L2 = programmed cell death-ligand 2; PTC = papillary thyroid cancer; TNM = tumor-node-metastasis; Treg = regulatory T cell.
|
30913016 |
2019 |
|
Malignant neoplasm of larynx
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 is highly expressed in the laryngeal cancer with the tumor microenvironment immunosuppression.
|
30361911 |
2019 |